SCHEMBL6457809

SCHEMBL6457809

CN(C)c1ccnc(NC2CCC(NC(=O)c3ccc(-c4cccc([N+](=O)[O-])c4)o3)CC2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
MAPT P10636 9/20 0.49
ALDH1A1 P00352 8/20 0.49
GAA P10253 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 1/20 0.49
KMT2A Q03164 6/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 3/20 0.49
MGAM O43451 1/20 0.49
SI P14410 1/20 0.49
MGAM2 Q2M2H8 1/20 0.49
ADRA2A P08913 1/20 0.47
MCHR1 Q99705 1/20 0.47
THRB P10828 1/20 0.46
RAC1 P63000 1/20 0.46
MAPK1 P28482 4/20 0.45
NPSR1 Q6W5P4 1/20 0.44
OPRM1 P35372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6457803 1.00 NPC1 (0.62) NPC1RAB9AMAPTALDH1A1GAA
SCHEMBL6458599 0.84 MCHR1 (0.65) ADRA2AMCHR1
SCHEMBL6458588 0.84 MCHR1 (0.65) ADRA2AMCHR1
SCHEMBL6876364 0.83 TDP1 (0.48) MAPTGAAL3MBTL1KDM4EKMT2A
SCHEMBL6876370 0.83 TDP1 (0.48) MAPTGAAL3MBTL1KDM4EKMT2A
SCHEMBL13793198 0.82 MCHR1 (0.73) NPC1RAB9AMAPTALDH1A1GAA
SCHEMBL6459234 0.82 NPC1 (0.62) NPC1RAB9AMAPTALDH1A1GAA
SCHEMBL6459229 0.82 NPC1 (0.62) NPC1RAB9AMAPTALDH1A1GAA
SCHEMBL6464741 0.82 NPC1 (0.47) NPC1RAB9AMAPTALDH1A1KMT2A
SCHEMBL6464736 0.82 NPC1 (0.47) NPC1RAB9AMAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 NPC1 778/4885RAB9A 1648/4885MAPT 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.